A - Human Necessities – 61 – L
Patent
A - Human Necessities
61
L
A61L 31/16 (2006.01) A61K 31/47 (2006.01) A61K 31/498 (2006.01) A61L 31/10 (2006.01) A61P 9/10 (2006.01)
Patent
CA 2352261
This invention is directed to quinoline/quinoxaline compounds of formula (I), which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising theses compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
La présente invention concerne des composés de quinoléine/quinoxaline représentés par la formule (I) qui inhibent le facteur de croissance d'origine plaquettaire ou l'activité de la tyrosine kinase p56?lck¿. Par ailleurs, cette invention concerne des compositions pharmaceutiques contenant les composés précités, ainsi que leur utilisation pour traiter un patient souffrant/sujet à des troubles/états impliquant la différenciation cellulaire, la prolifération cellulaire, la production de matrices extracellulaires ou la libération de médiateurs et/ou l'activation ou la prolifération des lymphocytes T.
He Wei
Maguire Martin P.
Myers Michael R.
Spada Alfred P.
Aventis Pharmaceuticals Inc.
Aventis Pharmaceuticals Products Inc.
Deeth Williams Wall Llp
LandOfFree
Quinoline and quinoxaline compounds as pdgf-receptor and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline and quinoxaline compounds as pdgf-receptor and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline and quinoxaline compounds as pdgf-receptor and/or... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2082243